0001209191-18-047874.txt : 20180821
0001209191-18-047874.hdr.sgml : 20180821
20180821200234
ACCESSION NUMBER: 0001209191-18-047874
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180817
FILED AS OF DATE: 20180821
DATE AS OF CHANGE: 20180821
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bujarski Robert Joseph
CENTRAL INDEX KEY: 0001333458
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-10961
FILM NUMBER: 181031254
MAIL ADDRESS:
STREET 1: C/O QUIDEL CORPORATION
STREET 2: 12544 HIGH BLUFF DRIVE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: QUIDEL CORP /DE/
CENTRAL INDEX KEY: 0000353569
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 942573850
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12544 HIGH BLUFF DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 8585521100
MAIL ADDRESS:
STREET 1: 12544 HIGH BLUFF DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: MONOCLONAL ANTIBODIES INC /DE/
DATE OF NAME CHANGE: 19910210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-08-17
0
0000353569
QUIDEL CORP /DE/
QDEL
0001333458
Bujarski Robert Joseph
12544 HIGH BLUFF DRIVE, SUITE 200
SAN DIEGO
CA
92130
0
1
0
0
SVP, Bus Dev & Gen Counsel
Common Stock
2018-08-17
4
M
0
7156
27.57
A
53537
D
Common Stock
2018-08-17
4
M
0
8798
23.41
A
62335
D
Common Stock
2018-08-17
4
M
0
17596
15.40
A
79931
D
Common Stock
2018-08-17
4
S
0
38550
70.1491
D
41381
D
Non-qualified Stock Options
27.57
2018-08-17
4
M
0
7156
0.00
D
2024-02-24
Common Stock
7156
0
D
Non-Qualified Stock Options
23.41
2018-08-17
4
M
0
8798
0.00
D
2025-02-05
Common Stock
8798
8798
D
Non-Qualified Stock Options
15.40
2018-08-17
4
M
0
17596
0.00
D
2026-02-10
Common Stock
17596
17596
D
The weighted average sale price for these transactions was $70.1491 per share, with a range of $69.755 to $70.71. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares sold at each separate price.
14,130 shares vested on 2/24/2016; 7,155 shares vested on 2/24/2017; 7,156 shares vested on 2/24/2018.
17,596 shares vested on 2/5/2017; 8,798 shares vested on 2/5/2018; 8,798 shares will vest on 2/4/2019.
17,596 shares vested on 2/10/2018; 8,798 shares will vest on 2/10/2019; 8,798 shares will vest on 2/10/2020.
All transactions reported herein were effected pursuant to a pre-established 10b5-1 trading plan.
Robert J. Bujarski
2018-08-21